Hadassah

Hadassah-Pluristem Trial Approved for Placental Cell Bone Marrow Regeneration

Monday, Feb 22 2016

The Federal Drug Administration (FDA) has approved the start of a Phase I trial with a placental-cell based therapy to mitigate acute radiation syndrome (ARS) and enhance bone marrow regeneration following a bone marrow transplant. The product, PLX-R18, was developed by Pluristem Therapeutics based on studies of Prof. Raphael Gorodetsky, head of Hadassah’s Biotechnology and Radiobiology Laboratories at the Sharett Institute of Oncology.

ARS (sometimes known as radiation toxicity or radiation sickness) is an acute lethal illness caused by irradiation of the entire body (or most of the body) by a high dose of penetrating radiation in a very short period of time. The syndrome affects the body’s ability to form new blood cells (hematopoietic recovery).

Prof. Gorodetsky and his colleagues helped Pluristem to identify the potency of the new cell product, having conducted an extensive preclinical study at Hadassah. The preclinical findings with PLX-R18 cells (also termed PLX-RAD) were initially published in PLOS-ONE (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066549) by Prof. Raphael Gorodetsky and the development team, and they were further verified at the National Institutes of Health (NIH) and other prominent centers in the United States. The new cell product’s mechanism of action was also explored in collaboration with the Charité Univeristy Medical Center in Berlin, where its researchers revealed that PLX-R18 cells secrete a wide range of specific proteins which could trigger the resurgence of the necessary early descendants of stem cells (progenitor cells) that can differentiate to form one or more kinds of cell and support the regeneration of all blood cell lineages.

The preclinical studies paved the way for PLX-R18’s application as a new treatment for cancer patients who suffer complications following high-dose radiation and chemotherapy. “PLX-R18-based therapy,” notes Prof. Gorodetsky, “may present a breakthrough in the lifesaving treatment of acute radiation syndrome, which so far has had very limited alternative treatments. It can be anticipated that this cell therapy may serve also as a safe and easy treatment for a variety of severe hematopoietic disorders.”

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Mar 22 2017

Marathon Runner Pays Tribute to Hadassah Medical Team

After successfully running in the 2017 Jerusalem Marathon, Gil Troy pays tribute to Prof. Meir Liebergall, Director of the Hadassah Medical Organization’s Orthopedic Surgery Department, and his medical team, who made this run possible.

READ MORE ›
alt_text

Wednesday, Mar 22 2017

Reversing the Odds with Technology and Expertise

It could be a young patient with a virulent flu. Or a man having a severe asthma attack. Or a pregnant woman with a complication of pregnancy.

READ MORE ›
alt_text

Wednesday, Mar 22 2017

Cypriot Health Minister Helps Save Israeli Patient

Whether it was a newborn baby with a severe heart defect or a pregnant woman with an unusual ectopic pregnancy, the Hadassah Medical Organization has been known to save the lives of Cypriot patients by helicoptering them to its hospital for complex emergency treatments. Recently, however, it was the Cypriot Health Minister who helped save the life of an Israeli patient.

READ MORE ›
alt_text

Wednesday, Mar 22 2017

Top-Tier Turkish Journalists Receive Inside View of Hadassah Hospital

A delegation of top-tier Turkish journalists, accompanied by representatives from the Israel Foreign Ministry, visited Hadassah Hospital Ein Kerem this month, marking the first time a high-level Turkish delegation has come to Israel since the new reconciliation agreement was signed between Israel and Turkey.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More